$KRRO

FORMELA JEAN FRANCOIS sold $6K of KRRO (indirect holdings)

FORMELA JEAN FRANCOIS sold 419 indirectly-held shares of Korro Bio, Inc. (KRRO) at $13.95 on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FORMELA JEAN FRANCOIS
Published Jun 1, 2026, 9:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRRO
Neutral
medium confidence
Mentioned
$KRRO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

The disclosed open-market sale may influence short-term sentiment, but the 10b5-1 designation generally lowers the likelihood of a strong directional fundamental signal.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a major repricing.

03

What to watch

The filing does not reveal whether other insiders increased/decreased holdings around the same time, which could matter more than a single director sale.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 1 for a May 28 sale

Background

This is an SEC Form 4 insider transaction disclosure for Korro Bio, Inc. (KRRO).

Company-level read

Ticker impact

$KRRONeutralMedium confidence
Context

Korro Bio director Formela Jean Francois sold 419 shares in an open-market transaction disclosed via SEC Form 4 on May 28.

Expected impact

Likely limited near-term impact; any reaction should be muted given the 10b5-1 pre-arranged nature.

Evidence & confidence

The filing provides a specific sale price/value but does not indicate distress, new guidance, or operational change; 10b5-1 plans typically reduce interpretive signal.

Market effects

Minimal; this is company-specific insider activity without sector-wide read-across.

None.

None.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • Korro Bio, Inc.

    Subject of the insider transaction disclosure (KRRO).

  • Formela Jean Francois

    Director who sold 419 shares under a pre-arranged 10b5-1 plan.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria